| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-10-09 | MIV-711 | bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases. |
1b | Medivir (Sweden) | Rheumatic diseases - Inflammatory diseases – Bone diseases |
| 2013-10-08 | new antibiotics | Fundación MEDINA (Spain) Cubist Pharmaceuticals (USA -MA) | Infectious diseases | ||
| 2013-10-05 | omalizumab | chronic spontaneous urticaria (CSU) |
3 | Novartis (Switzerland) | Dermatological diseases |
| 2013-10-03 | ADX71441 | anxiety, pain, overactive bladder, alcohol addiction, Charcot-Marie-Tooth 1A disease | preclinical | Addex Therapeutics (Switzerland) | CNS diseases - Rare diseases - Neurodegenerative diseases |
| 2013-10-03 | ATL101 (Lutetium-177 anti-PSMA antibody) | metastatic castrate-resistant prostate cancer (mCRPC) | 1 | Atlab Pharma (France) | Cancer - Oncology |
| 2013-10-03 | brodalumab (AMG 827) | moderate to severe psoriasis |
2 | Amgen (USA) AstraZeneca (UK) | Autoimmune diseases – Dermatological diseases |
| 2013-10-03 | Aubagio® (teriflunomide) | multiple sclerosis | 3 | Genzyme (USA - MA), a Sanofi company (France) | Autoimmune diseases - Neurodegenerative diseases |
| 2013-10-02 | TRO40303 | acute myocardial infarction
|
2 | Trophos (France) | Cardiovascular diseases |
| 2013-10-01 | laquinimod | multiple sclerosis | 3 | Teva Pharmaceuticals (Israel) Active Biotech (Sweden) | Autoimmune diseases - Neurodegenerative diseases |
| 2013-10-01 | NGR-hTNF | soft tissue sarcoma |
2 | MolMed (Italy) | Cancer - Oncology |
| 2013-10-01 | ToleroMune® grass allergy vaccine | grass allergy |
2 | Circassia (UK) | Allergic diseases - Immune diseases |
| 2013-09-28 | Kadcyla® (trastuzumab emtansine (T-DM1) | advanced HER2-positive breast cancer (metastatic or locally recurrent unresectable) who have received at least two prior treatments including Herceptin, lapatinib and a taxane |
3 | Roche (Switzerland) | Cancer - Oncology |
| 2013-09-25 | Yondelis® (trabectedin) | unresectable malignant pleural mesothelioma | 2 | PharmaMar, Zeltia Group (Spain) | Cancer - Oncology |
| 2013-09-18 | CT327 (TrkA kinase inhibitor ) | atopic dermatitis |
2b | Creabilis (Luxembourg) | Dermatological diseases - Immunological diseases - Inflammatory diseases |
| 2013-09-18 | GWP42006 | epilepsy |
1 | GW Pharmaceuticals (UK) | CNS diseases - Neurological diseases |
| 2013-09-17 | Somatuline® (lanreotide) | control of symptoms in patients with neuroendocrine tumors (NETs) associated with carcinoid syndrome |
3 | Ipsen (France) | Cancer - Oncology |
| 2013-09-17 | apalutamide (ARN-509, JNJ-56021927) | prostate cancer | 3 | Aragon Pharmaceuticals (USA - CA), now Johnson&Johnson (J&J) (USA - NJ) | Cancer - Oncology |
| 2013-09-16 | ISA101 | anal intraepithelial neoplasia (AIN) | 1-2 | ISA Pharmaceuticals (The Netherlands) | Cancer - Oncology - Infectious diseases |
| 2013-09-13 | resminostat (oral pan-histone deacetylase (HDAC) inhibitor) | advanced liver cancer - hepatocellular carcinoma | 2 | 4SC (Germany) | Cancer Oncology |
| 2013-09-12 | House Dust Mite (HDM)-SPIRE | house dust mite allergy | 2 | Circasssia (UK) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
